Loading resource…

National Institute for Health and Care Excellence (NICE)
The guidance outlines the criteria under which dapagliflozin should be funded as an add-on treatment to optimized standard care for patients with CKD. It emphasizes the importance of considering individual patient needs and the responsibilities of healthcare professionals in applying these recommendations. The document also discusses the evaluation process and the roles of the NICE committee members involved in the appraisal.
No account needed